102 related articles for article (PubMed ID: 23077229)
1. Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration.
Querques G; Massamba N; Coscas F; Forte R; Souied EH
Br J Ophthalmol; 2012 Dec; 96(12):1479-83. PubMed ID: 23077229
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal ranibizumab versus thermal laser photocoagulation in the treatment of extrafoveal classic choroidal neovascularization secondary to age-related macular degeneration.
Ladas ID; Chatziralli IP; Kotsolis AI; Douvali M; Georgalas I; Theodossiadis PG; Rouvas AA
Ophthalmologica; 2012; 228(2):93-101. PubMed ID: 22571933
[TBL] [Abstract][Full Text] [Related]
3. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization.
Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N
Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461
[TBL] [Abstract][Full Text] [Related]
5. [Intravitreal ranibizumab injection for the treatment of idiopathic choroidal neovascularisation in young patients].
Ouhadj O; Degheb N; Idir S; Nebab A; Nouri MT
J Fr Ophtalmol; 2012 Sep; 35(7):514-22. PubMed ID: 22789650
[TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for exudative age-related macular degeneration: 24-month outcomes from a single-centre institutional setting.
Querques G; Azrya S; Martinelli D; Berboucha E; Feldman A; Pece A; Coscas G; Soubrane G; Souied EH
Br J Ophthalmol; 2010 Mar; 94(3):292-6. PubMed ID: 19951942
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.
Amaro MH; Roller AB
Arq Bras Oftalmol; 2012; 75(4):273-6. PubMed ID: 23258660
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab for choroidal neovascularization in angioid streaks.
Mimoun G; Tilleul J; Leys A; Coscas G; Soubrane G; Souied EH
Am J Ophthalmol; 2010 Nov; 150(5):692-700.e1. PubMed ID: 20719301
[TBL] [Abstract][Full Text] [Related]
10. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.
Stangos AN; Gandhi JS; Nair-Sahni J; Heimann H; Pournaras CJ; Harding SP
Am J Ophthalmol; 2010 Nov; 150(5):666-73. PubMed ID: 20719300
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up.
Lorenzo D; Arias L; Alcubierre R; Pujol O; Caminal JM; Rubio M; Català J; Garcia-Bru P; Arruga J
Ophthalmologica; 2011; 226(3):103-9. PubMed ID: 21720153
[TBL] [Abstract][Full Text] [Related]
12. The development of choroidal neovascularization in eyes with the geographic atrophy form of age-related macular degeneration.
Sunness JS; Gonzalez-Baron J; Bressler NM; Hawkins B; Applegate CA
Ophthalmology; 1999 May; 106(5):910-9. PubMed ID: 10328389
[TBL] [Abstract][Full Text] [Related]
13. Angiographic regression patterns after intravitreal ranibizumab injections for neovascular age-related macular degeneration.
Tran TH; Querques G; Forzy G; Souied EH
Ophthalmic Surg Lasers Imaging; 2011; 42(6):498-508. PubMed ID: 21830744
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1250-9. PubMed ID: 22446886
[TBL] [Abstract][Full Text] [Related]
15. Fundus Autofluorescence Changes After Ranibizumab Treatment for Subfoveal Choroidal Neovascularization Secondary to Pathologic Myopia.
Parodi MB; Iacono P; Sacconi R; Iuliano L; Bandello F
Am J Ophthalmol; 2015 Aug; 160(2):322-327.e2. PubMed ID: 25935099
[TBL] [Abstract][Full Text] [Related]
16. Three years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopia.
Hefner L; Riese J; Gerding H
Klin Monbl Augenheilkd; 2013 Apr; 230(4):401-4. PubMed ID: 23629791
[TBL] [Abstract][Full Text] [Related]
17. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
18. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration.
Bolz M; Simader C; Ritter M; Ahlers C; Benesch T; Prünte C; Schmidt-Erfurth U
Br J Ophthalmol; 2010 Feb; 94(2):185-9. PubMed ID: 19692384
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study).
Nguyen QD; Schachar RA; Nduaka CI; Sperling M; Klamerus KJ; Chi-Burris K; Yan E; Paggiarino DA; Rosenblatt I; Aitchison R; Erlich SS;
Ophthalmology; 2012 Sep; 119(9):1867-73. PubMed ID: 22683252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
